InsiderSignal.AI

InsiderSignal.ai

LENZ - Lenz Therapeutics, Inc.

Insider Purchase by George Jeffrey P. (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, George Jeffrey P., serving as Dir at Lenz Therapeutics, Inc. (LENZ), purchased 5,592 shares at $8.92 per share, for a total transaction value of $49,890.00. Following this transaction, George Jeffrey P. now holds 5,592 shares of LENZ.

The trade was executed on Friday, March 27, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 30, 2026, 3 days after the trade was made.

Lenz Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

George Jeffrey P.

George Jeffrey P.

Dir

Jeffrey P. George (also known as Jeff George) is the Chairperson of the Board of Directors at LENZ Therapeutics, Inc. (NASDAQ: LENZ), a late-stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia.[[1]](https://www.georgefamilyfoundation.org/jeff-george-bio)[[4]](https://www.futunn.com/en/stock/LENZ-US/company)[[5]](https://www.businesswire.com/news/home/20240321281097/en/LENZ-Therapeutics-Announces-Completion-of-Merger-with-Graphite-Bio-and-Provides-Update-on-Recent-Clinical-and-Corporate-Progress) He recently engaged in securities transactions as a director of the company, with his address listed at LENZ's Solana Beach, CA headquarters.[[3]](https://ir.lenz-tx.com/sec-filings/content/0001815776-25-000048/wk-form4_1749678400.html)[[4]](https://www.futunn.com/en/stock/LENZ-US/company) George is the Managing Partner and founder of Maytal Capital, a healthcare-focused venture capital and private equity firm established in 2017.[[1]](https://www.georgefamilyfoundation.org/jeff-george-bio)[[6]](https://theorg.com/org/lenztx/org-chart/jeff-george) His career highlights include serving as global CEO of Sandoz (Novartis's generics division) and Alcon (eye care division) from 2008 to 2016, both on Novartis's Executive Committee, with each generating around $10 billion in revenue at the time.[[1]](https://www.georgefamilyfoundation.org/jeff-george-bio) He holds board positions at Amneal Pharmaceuticals (NASDAQ: AMRX), 908 Devices (NASDAQ: MASS), and others, and previously chaired Lykos Therapeutics.[[1]](https://www.georgefamilyfoundation.org/jeff-george-bio)[[6]](https://theorg.com/org/lenztx/org-chart/jeff-george) George earned an MBA from Harvard Business School, a Master's from Johns Hopkins SAIS, and a B.A. from Carleton College.[[6]](https://theorg.com/org/lenztx/org-chart/jeff-george)

View full insider profile →

Trade Price

$8.92

Quantity

5,592

Total Value

$49,890.00

Shares Owned

5,592

Trade Date

Friday, March 27, 2026

9 days ago

SEC Filing Date

Monday, March 30, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Lenz Therapeutics, Inc.

Company Overview

No company information available
View news mentioning LENZ

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5217451

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime